Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors

Basit Öğe Kaydı
dc.contributor.authorSezgin, C
dc.contributor.authorKarabulut, B
dc.contributor.authorUslu, R
dc.contributor.authorSanli, UA
dc.contributor.authorGoksel, G
dc.contributor.authorYuzer, Y
dc.contributor.authorGoker, E
dc.date.accessioned2019-10-27T19:21:59Z
dc.date.available2019-10-27T19:21:59Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. Most patients with pancreatic cancer show an inoperable locally advanced/ metastatic tumour at the time of diagnosis. The present study was aimed at determining the prognostic factors in patients with advanced pancreatic carcinoma treated with gemcitabine. Material and methods. Sixty- seven unresectable or metastatic pancreatic cancer patients treated with gemcitabine were included in the study and a total of 258 cycles of treatment were applied. Results. The overall response rate was 5%. Thirty- one percent of the patients had stable disease, whereas progressive disease was seen in 49%. Clinical benefit response rate was 15%. The median duration of response was 7.3 months. Median progression- free survival was 3 months, while median overall survival was 9 months. Univariate analysis revealed that worse results were found in patients with performance status ( PS) = 2, and in patients with primary tumour location in the body or tail of the pancreas ( p < 0.05). Multivariate analysis of data revealed that the most important factor was PS of the patient, as the patients with PS = 2 had worse results than the patients with PS = 0 - 1 ( p < 0.05). Conclusions. Low PS is a negative predictive factor for the survival of patients with advanced pancreatic carcinoma treated with gemcitabine.en_US
dc.identifier.doi10.1080/00365520510023819en_US
dc.identifier.endpage1492en_US
dc.identifier.issn0036-5521
dc.identifier.issn1502-7708
dc.identifier.issue12en_US
dc.identifier.pmid16293561en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1486en_US
dc.identifier.urihttps://doi.org/10.1080/00365520510023819
dc.identifier.urihttps://hdl.handle.net/11454/39043
dc.identifier.volume40en_US
dc.identifier.wosWOS:000233957500016en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofScandinavian Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectgemcitabineen_US
dc.subjectpancreatic carcinomaen_US
dc.subjectprognostic factorsen_US
dc.subjectsurvivalen_US
dc.titleGemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu